OncoSec Medical is a biopharmaceutical company focused on developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy for treating solid tumor cancers. The company has based its core technology on its proprietary use of an electroporation platform that dramatically enhances delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treating solid cancers with these targeted anti-cancer agents has resulted in selective destruction of cancerous cells while sparing healthy normal tissues. For more information, visit the company’s Web site at www.oncosec.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: